Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Ductal Carcinoma
Interventions: DRUG: Docetaxel|DRUG: Doxorubicin
Sponsor: Sanofi